Killing the Unkillable Cancer Cells
Revolutionary Cancer Therapeutics
Innate Repair is a preclinical-stage Biotech developing a new therapeutic approach for cancer, with an initial focus on aggressive brain tumors.
​
We utilize siRNA technology to target the Hes3 Signaling Axis, a molecular mechanism that acts as the Achilles Heel for the cancer stem cells, i.e. those cancer cells that evade current therapies and help the tumor regenerate.
Innate Repair made the "Ones to Watch" list in the 2024 competition!
Targeting the Hes3 Signaling Axis
An untapped biochemical mechanism
Innate Repair scientists discovered a new molecular mechanism that normal tissues use to promote regeneration after injury. Cancerous tissues exploit it and use it as an alternative way of growing. Targeting the Hes3 Signaling Axis is a completely new anti-cancer approach.
Our Science
Revolutionary biochemistry
01
New and Transformative
Pursuing a new molecular mechanism for the first time will open vast opportunities in brain and other types of cancer.
02
Safety & Scalability
Our molecular target is only expressed in regenerating tissue and cancerous tissue. Mice lacking the target are healthy.
We start with a focus on brain cancer (glioblastoma). However, the work is expandable to many other cancer types.
03
Protected & Validated
Our IP-protected approach has been validated in multiple systems (biopsies, animal models, in vitro efficacy).
04
A Vast body of work
22+ years of research with publications in top journals (Nature, PNAS, Diabetes, J Biol Chem etc.) and multiple patents.
Top labs around the world have independently corroborated and extended our published findings.
Publications
Selected peer-reviewed publications
01
Discovery of the Hes3 Axis. Disease modification in ischemic stroke models by its pharmacological over-activation.
02
Disease modification in Parkinsonian models by the pharmacological over-activation of the Hes3 Axis.
03
Disease modification in Parkinsonian models by over-activation of the Hes3 Axis and protection of the vasculature.
04
Killing of cultured glioma cancer stem cells by blocking the Hes3 Axis (with the use of an anti-Hes3 siRNA).
05
Demonstration that the Hes3 Axis is important for the protection and regeneration of the endocrine pancreas.
06
The Hes3 Axis promotes pancreatic regeneration after injury with powerful consequences in models of type 1 diabetes.
07
Pancreatic damage, high fat diet, metformin administration, and aging regulate the Hes3 Axis in the brain.
08
Glioma cancer stem cells can turn on and off the Hes3 Axis. Different means of killing them are needed in the two states.
About Us
The Company
​
We are a spin off from the Technische Universitaet Dresden. Through its corporate arm, TUD AG, the University is a shareholder of our parent holding Company, Innate Repair Ltd, which has exclusive rights to additional, oncology related IP. Our team comprises the discoverer of the Hes3 Signaling Axis, investors, medics, and company creators.
Equality, Diversity, Inclusion
Our mission is to help people with serious diseases, together with anyone who can contribute. There is no room for exclusion on this quest. So, bring everything you have and everything you are and you will fit right in.
Team
Become a part of our journey!
Together with our partners Capital Cell we have started an equity-based crowdfunding campaign.
We are delighted to invite you to own a part of Innate Repair and share in its future by investing as little as 1,000E.